365telugu.com online news,India,November 12, 2025:OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) reported robust consolidated results for Q2FY26 (ended September 30, 2025), driven by strong execution in MSAs, IP-led business momentum, and strategic capacity expansion.
Q2FY26 Performance Highlights
- Revenue: ₹3,758 million, +12% YoY, +15% QoQ
- EBITDA: ₹1,065 million, +37% YoY, +20% QoQ
- EBITDA Margin: 28%, up ~506 bps YoY, ~130 bps QoQ
- Adjusted PAT: ₹449 million (vs loss in Q2FY25), +21% QoQ
- Adjusted EPS: ₹3.9, +21% QoQ
Financial Snapshot (₹ million)
| Particulars | Q2FY26 | QoQ % | YoY % | H1FY26 | YoY % |
|---|---|---|---|---|---|
| Revenue | 3,758 | +15% | +12% | 7,030 | +12% |
| EBITDA | 1,065 | +20% | +37% | 1,950 | +37% |
| EBITDA Margin | 28% | ~130 bps | ~506 bps | 28% | ~504 bps |
| Adjusted PAT¹ | 449 | +21% | Loss → Profit | 820 | Loss → Profit² |
| Adjusted EPS (₹)¹ | 3.9 | +21% | – | 7.2 | – |
Adjusted for exceptional items & scheme-related intangible amortization Excludes one-time tax asset (₹411m in Q1FY25)
Strategic Acquisitions Fuel Growth
The recently approved proposed acquisition of Poland and Brooks contributed significantly in H1FY26:
- Combined Revenue: $29 million
- EBITDA: $11 million
- Margin: 38%
Mr. Neeraj Sharma, CEO & MD, commented:
“Q2 was powered by strong MSA execution and growth in our IP-led portfolio. We are fast-tracking DDC capacity to support upcoming customer launches. With the proposed multi-dose fill-finish site in Europe and integrated carbapenem facility in India, we are confident in upgrading our FY28 revenue guidance to $500 million+.”
Source: OneSource Specialty Pharma Limited..